BriaCell Therapeutics Corp. (TSXV: BCT) announced today that they have received gross proceeds from exercised warrants amounting to US$12.9 million. This is in connection with a number of company units sold from a previously concluded public offering earlier this year.
The proceeds came from 2.43 million common share purchase warrants sold at an exercise price of $5.31 per common share. These issued warrants were part of the units sold by the company in connection with their offering back in February.
The company announced that they intend to use net proceeds from the warrant exercises to further advance their clinical research for breast cancer treatment, and for its development pipeline to explore applications of their platform technology for other types of cancer in addition to breast cancer, as well as for general corporate purposes.
BriaCell Therapeutics Corp. last traded at C$7.15 on the TSX.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.